Cargando…
A Case-Only Genome-Wide Interaction Study of Smoking and Bladder Cancer Risk: Results from the COBLAnCE Cohort
SIMPLE SUMMARY: Bladder cancer is one of the most common cancers worldwide. The most important known cause of bladder cancer is tobacco smoking. Several genetic variations are also linked to the risk of developing bladder cancer. In this study, we focused on how smoking behavior interacts with genes...
Autores principales: | Karimi, Maryam, Mendez-Pineda, Sebastian, Blanché, Hélène, Boland, Anne, Besse, Céline, Deleuze, Jean-François, Meng, Xiang-Yu, Sirab, Nanor, Groussard, Karine, Lebret, Thierry, Bonastre, Julia, Allory, Yves, Radvanyi, François, Benhamou, Simone, Michiels, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487226/ https://www.ncbi.nlm.nih.gov/pubmed/37686494 http://dx.doi.org/10.3390/cancers15174218 |
Ejemplares similares
-
A prospective multicenter study on bladder cancer: the COBLAnCE cohort
por: Benhamou, Simone, et al.
Publicado: (2016) -
Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers
por: Lebret, Thierry, et al.
Publicado: (2015) -
Deregulation of Rab and Rab Effector Genes in Bladder Cancer
por: Ho, Joel R., et al.
Publicado: (2012) -
A Novel Epigenetic Phenotype Associated With the Most Aggressive Pathway of Bladder Tumor Progression
por: Vallot, Céline, et al.
Publicado: (2011) -
Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial
por: Pfister, Christian, et al.
Publicado: (2020)